A
Alexander M. Lesokhin
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 211
Citations - 15892
Alexander M. Lesokhin is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Multiple myeloma. The author has an hindex of 33, co-authored 138 publications receiving 12832 citations. Previous affiliations of Alexander M. Lesokhin include Cornell University & Bristol-Myers Squibb.
Papers
More filters
Journal ArticleDOI
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok,Harriet Kluger,Margaret K. Callahan,Michael A. Postow,Naiyer A. Rizvi,Alexander M. Lesokhin,Neil H. Segal,Charlotte E. Ariyan,Ruth-Ann Gordon,Kathleen Reed,Matthew M. Burke,Anne Caldwell,Stephanie Anne Kronenberg,Blessing Agunwamba,Xiaoling Zhang,Israel Lowy,Hector David Inzunza,William Feely,Christine Horak,Quan Hong,Alan J. Korman,Jon M. Wigginton,Ashok Kumar Gupta,Mario Sznol +23 more
TL;DR: Conurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients.
Journal ArticleDOI
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell,Alexander M. Lesokhin,Alexander M. Lesokhin,Ivan Borrello,Ahmad Halwani,Emma C. Scott,Martin Gutierrez,Stephen J. Schuster,Michael Millenson,Deepika Cattry,Gordon J. Freeman,Scott J. Rodig,Bjoern Chapuy,Azra H. Ligon,Lili Zhu,Joseph F. Grosso,Su Y oung Kim,John M. Timmerman,Margaret A. Shipp,Philippe Armand +19 more
TL;DR: Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma.
Journal ArticleDOI
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow,Margaret K. Callahan,Margaret K. Callahan,Christopher A. Barker,Christopher A. Barker,Yoshiya Yamada,Yoshiya Yamada,Jianda Yuan,Shigehisa Kitano,Zhenyu Mu,Teresa S. Rasalan,Matthew Adamow,Erika Ritter,Christine Sedrak,Achim A. Jungbluth,Ramon Chua,Arvin Yang,Ruth Ann Roman,Samuel Rosner,Brenna Benson,James P. Allison,Alexander M. Lesokhin,Alexander M. Lesokhin,Sacha Gnjatic,Jedd D. Wolchok,Jedd D. Wolchok,Jedd D. Wolchok +26 more
TL;DR: A case of the abscopal effect is reported in a patient with melanoma treated with ipilimumab and radiotherapy, with temporal associations of tumor shrinkage with antibody responses to the cancer-testis antigen NY-ESO-1, changes in peripheral-blood immune cells, and increases in antibodies to other antigens after radiotherapy.
Journal ArticleDOI
Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study
Alexander M. Lesokhin,Alexander M. Lesokhin,Stephen M. Ansell,Philippe Armand,Emma C. Scott,Ahmad Halwani,Martin Gutierrez,Michael Millenson,Adam D. Cohen,Stephen J. Schuster,Daniel Lebovic,Madhav V. Dhodapkar,David Avigan,Bjoern Chapuy,Azra H. Ligon,Gordon J. Freeman,Scott J. Rodig,Deepika Cattry,Lili Zhu,Joseph F. Grosso,M. Brigid Bradley Garelik,Margaret A. Shipp,Ivan Borrello,John M. Timmerman +23 more
TL;DR: Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas and PD-L1/PD-L2 locus integrity and protein expression.
Journal ArticleDOI
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo,Xuan Wang,Xuan Wang,Xuan Wang,Kaitlin M. Woo,Kaitlin M. Woo,Tunc Iyriboz,Tunc Iyriboz,Darragh Halpenny,Jane Cunningham,Jane Cunningham,Jamie E. Chaft,Jamie E. Chaft,Neil H. Segal,Neil H. Segal,Margaret K. Callahan,Margaret K. Callahan,Alexander M. Lesokhin,Alexander M. Lesokhin,Jonathan E. Rosenberg,Jonathan E. Rosenberg,Martin H. Voss,Martin H. Voss,Charles M. Rudin,Charles M. Rudin,Hira Rizvi,Hira Rizvi,Xue Hou,Xue Hou,Katherine Rodriguez,Katherine Rodriguez,Melanie Albano,Ruth Ann Gordon,Ruth Ann Gordon,Charles Leduc,Charles Leduc,N. Rekhtman,N. Rekhtman,Bianca Harris,Bianca Harris,Alexander M. Menzies,Alexander M. Menzies,Alexander D. Guminski,Matteo S. Carlino,Matteo S. Carlino,Benjamin Y. Kong,Benjamin Y. Kong,Jedd D. Wolchok,Jedd D. Wolchok,Michael A. Postow,Georgina V. Long,Matthew D. Hellmann,Matthew D. Hellmann +52 more
TL;DR: Pneumonitis associated with anti- PD-1/PD-L1 mAbs is a toxicity of variable onset and clinical, radiologic, and pathologic appearances that is more common when anti-PD-1-L 1 mAbs are combined withAnti-cytotoxic T-cell lymphocyte-4 mAb.